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http://www.translational-medicine.com/content/11/1/28RESEARCH Open AccessMesenchymal stem cells enhance ovarian cancer
cell infiltration through IL6 secretion in an
amniochorionic membrane based 3D model
Cyril Touboul1,2†, Raphael Lis1,3†, Halema Al Farsi1, Christophe M Raynaud1, Mohamed Warfa1, Hamda Althawadi1,
Eliane Mery4, Massoud Mirshahi2 and Arash Rafii1,3,5*Abstract
Background: The early peritoneal invasion of epithelial ovarian cancer (EOC) by tumoral aggregates presents in
ascites is a major concern. The role of the microenvironment seems to be important in this process but the lack of
adequate models to study cellular interactions between cancer cells and stromal cells does not allow to uncover
the molecular pathways involved. Our goal was to study the interactions between ovarian cancer cells (OCC) and
mesenchymal stem cells (MSC) using a 3D model.
Methods: We used millimetric pieces of amniochorionic membrane - referred to as amniotic membrane scaffold
(AMS) - to create 3D peritoneal nodules mimicking EOC early invasion. We were able to measure the distribution
and the depth of infiltration using confocal microsopy. We extracted MSC from the amniochorionic membrane
using the markers CD34-, CD45-, CD73+, CD90+, CD105+ and CD29+ at the Fluorescence Activated Cell Sorting
(FACS) analysis. We used transwell and wound healing tests to test OCC migration and invasion in vitro.
Results: Here we show that OCC tumors were located in regions rich in MSC (70%). The tumors infiltrated deeper
within AMS in regions rich in MSC (p<0.001). In vitro tests revealed that higher IL6 secretion in a context of
MSC-OCC co-culture could enhance migration and invasion of OCC. After IL6 receptor antagonism, OCC infiltration
was significantly decreased, mostly in regions rich in MSCs, indicating that recruitment and tridimensional invasion
of OCC was dependent of IL6 secretion.
Conclusions: The use of tridimensional models using AMS could be a useful tool to decipher early molecular
events in ovarian cancer metastasis. Cytokine inhibitors interrupting the cross-talk between OCCs and MSCs such as
IL6 should be investigated as a new therapeutic approach in ovarian cancer.
Keywords: Ovarian cancer, IL6, Tumor infiltration, 3d model, Mesenchymal stem cellBackground
Epithelial Ovarian carcinoma (EOC) is the sixth most
common malignancy in woman and the leading cause of
death from gynecological cancer [1,2]. One of the main
differences between EOC and other neoplasm is burden of
local extension. Indeed tumor cells spread leads rapidly to
peritoneal carcinosis. Hence the majority of mortality in* Correspondence: jat2021@qatar-med.cornell.edu
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reproduction in any medium, provided the orEOC is due to extensive peritoneal disease, with an overall
survival ranging from 20 to 30% at 5 year [3].
While many studies in the literature address the issue
of distant metastasis through blood circulation, the bio-
logy of peritoneal tumor spread in advanced EOC is not
well known. Development of peritoneal carcinomatosis
involves well-defined critical steps, including cells shed-
ding and transport, interaction and adhesion to meso-
thelial layer, as well as colonization and proliferation
into the sub-mesothelial microenvironment [4]. During
the invasion of the sub-mesothelium ovarian cancer
cells (OCC) interact with a complex stroma containing
cells such as inflammatory cells and mesenchymal steml Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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role of the microenvironnement in EOC peritoneal
spreading. Bourguignon et al. enlightened the involve-
ment of hyaluronan-CD44 (hyaluronan receptor) in
early adhesion of OCC to peritoneal sheath [5]. We
have previously demonstrated the role of MSC in ova-
rian tumor growth and resistance to therapy [6-8]. The
lack of optimal models to mimic peritoneal extension is
a limitation to decipher molecular events implicated in
the interaction between cancer and stromal cells. In-
deed most OCC exfoliate in the peritoneal cavity and
evolve as tumoral aggregates. Hence, classical 2D cul-
tures might not represent an ideal model to reproduce
stepwise metastasis initiation [9].
The peritoneum is a complex organ composed by the
mesothelium, a simple squamoid epithelium lining also the
pleural and pericardial cavities. This surface epithelium is
attached to a basement membrane lying on a stroma of
variable thickness constituted by a collagen-based matrix,
blood and lymphatic vessels, nerve fibers, and, in the nor-
mal state, rare hematogenous cells [10]. Two joint mem-
branes compose the amniochorionic membrane (AM): the
amnion and the chorion. The amnion is composed by a
monolayer of epithelial cells separated from a mesenchymal
cellular stroma by a thick basement membrane [11]. It has
been used in various studies to mimick the peritoneum
[12,13]. The rich content of MSCs in the amniochorionic
membrane might also be an optimal tool to understand the
interaction between cancers cells and stromal cells [11,14].
In this study, we hypothesized that MSCs could play a
role in the infiltration of OCC in the sub-mesothelial
layer. We demonstrated that AMS is an appropriate tool
to study early adhesion of OCC aggregates to epithelial
sheath and early invasion into sub-mesothelial layer. We
were able to correlate the distribution of OCCs infiltra-
tion with the presence of MSC within the AMS. IL6 was
found as a factor secreted in co-culture between MSC
and OCC and was a determinant factor for OCC infiltra-
tion within the AMS.Material and methods
Culture of ovarian cancer aggregates with amniochorionic
membrane
We used OVCAR 3 and SKOV 3 cell lines previously trans-
fected with eGFP label. Fifty thousand ovarian cancer cells
(OCC) were cultivated in ultralow attachment 48 well plate
(Corning) in DMEM/F12 (1:1) (Hyclone) basal media sup-
plemented with 2 mM L-Glutamine (Hyclone), 1 × Non
Essential Amino Acid (NEAA) (Hyclone), PenStrepAmpB
(Sigma), 20 ng/ml basic Fibroblast Growth Factor (bFGF)
(Peprotech), 20 ng/ml Epidermal Growth Factor (EGF)
(Peprotech), 5 μg/ml Insulin (Sigma), 2% B27 supplements
(Invitrogen) and 4% basement matrigel (BD Biosciences).Cultures were incubated in humidified 5% CO2 incubators
and the media was replaced every 3 days.
Following approval form the Internal review Board
(HMC- IRB protocol 9109/09, Weill Cornell Medical
College in Qatar), placenta and amniochorionic membranes
were collected from donors at Woman’s Hospital at Hamad
Medical Corporation immediately after elective caesarean
section in the absence of labor, preterm rupture of mem-
brane-chorioamniontitis. The amniochorionic membrane
was washed with PBS and red blood cells were removed
using RBC lysis buffer (eBiosciences). Millimetric pieces of
amniochorionic membrane (referred to as amniotic mem-
brane scaffold (AMS)) were co-cultivated with the OCC.
Fluorescence activated cell sorting (FACS) analysis
Amniochorionic membrane was washed with PBS and red
cells were removed with RBC lysis buffer (eBiosciences).
We then chunked and digested the membrane in a pre-
warmed cocktail of Dispase 2 (1 mg/ml, Stem Cells Inc)
and Collagenase/Hyaluronidase (300 μg/ml and 100 μg/ml
respectively, Stem Cells Inc) during 45 minutes at 37°C.
We then filtered the digested tissue in a 100 μm filter and
obtained a cell suspension. Cell suspension was stained
with Mouse anti-human CD45 antibody (BD Biosciences,
#339192, clone 2D1) coupled with Amcyan, Mouse anti-
human CD34 (BD Biosciences, #555821, clone 581)
coupled with FITC, Mouse anti-human CD105 (biolegend,
#323212, clone 43A3) coupled with AF647, Mouse anti-
human CD73 (BD Biosciences, #550257, clone AD2)
coupled with PE, Mouse anti-human CD29 (biolegend,
#323212, clone TS2/16) coupled with APC-Cy7, Mouse
anti-human CD90 (BD Biosciences, #550402, clone 5E10)
coupled with AF700, Mouse anti-human CD44 (BD Bios-
ciences, #555479, clone G44-26) coupled with PE.
Briefly, 1.106 cells were harvested and non-specific
binding prevented by blocking in PBS- 5% FBS-1% BSA-
10% FcR Blocking Reagent (Myltenyi Biotec) for 30 min-
utes on ice. Cell suspension was incubated with specific
antibodies for 45 minutes on ice. Filtered, single-cell sus-
pension was analyzed by Fluorescence Activated Cell
Sorting (FACS) on a SORP FACSAria2 (BD Biosciences).
Data were processed with FACSDiva 6.3 software (BD
Biosciences). Doublets were excluded by FSC-W × FSC-
H and SSC-W × SSC-H analysis, single stained channels
were used for compensation, and fluorophore minus one
(FMO) controls were used for gating, 500 000 events
were acquired per sample.
Confocal analysis
Tumors were washed two times with PBS and fixed with
paraformaldehyde 3.7% (Sigma) before staining. The
antibodies used were the mouse anti human CD73_APC
(Biolegend, #344006, clone AD2) and CD90_PerCP-
Cy5.5 (Biolegend, #328118, clone 5E10). The non-
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serum albumin and 0.5% HS during one hour. Tumors
were incubated with the antibodies and FcR bloking
reagent (Miltenyi, #120-000-442) overnight and washed
third in PBS. Slides were mounted with the Fluoromount
Kit containing 4-, 6-diamidino-2- phenylindole (Invitro-
gen) to counterstain the nuclei. The slides were analyzed
with a Zeiss confocal microscope Laser Scanning Micro-
scope 710 (Carl Zeiss). Pictures were analyzed with Zen
2008 V5,0,0228 software (Carl Zeiss).
Cytokine array
Cell culture supernatant was collected and proteins quan-
tified based on Bradford assay. 200 μg of protein was
loaded on R&D systemW Human Cytokine Antibody Array
panel A (R&D systemW) according to manufacturer’s
instructions. Arrays were revealed using HorseRadish
Peroxidase (HRP) and SuperSignal West Pico Chemilu-
minescent Substrate (Thermo Scientific). Data were col-
lected using Geliance CCD camera (Perkin Elmer), and
extracted using ImageJ software (NIH). Briefly pictures
were inverted and background subtracted. We defined
a120 micron diameter area signal capture for all spots. We
defined our signal as the median pixel density value. For
comparison, independent array values were normalized on
their positive control intensity values.
Migration and invasion assays
Wound healing assay
OCC OVCAR3 (50 000 cells/well) were plated in 24-well
plates in triplicate for each condition. The cells were
starved from serum during 24 hours in a serum free cyto-
kine free context. The same straight scratch was made in
all the wells with a 1 μL pipette tip. After washing the well
with PBS to remove the detached cells, a fresh medium
containing specific molecule for each condition was used,
including positive control 20% serum medium and nega-
tive control serum-free, cytokine-free medium. The cyto-
kines IL6 (100 ng/ml, #20006 PeproTech), IL8 (100 ng/ml,
#20008 PeproTech), TNFa (100 ng/ml, #AF-30001A
PeproTech) and Rantes (100 ng/ml, #30006 PeproTech)
were added as indicated. Photos were taken and the rate
of closure was determined at 6, 12, 24 and 48 hours.
Experiments were performed in triplicate.
Migration and invasion assays
Assays were done in invasion chambers pre-coated with
reduced growth factor matrix from BD Biosciences. 50
000 viable cells were added to the upper chamber in
200 mL of serum-free medium and incubated in 5% CO2
at 37°C. For invasion assays, the lower chamber was filled
with 600 mL of specific medium for each condition:
100 ng/mL IL6, 100 ng/mL IL8, 100 ng/mL Rantes,
100 ng/mL TNFa, positive and negative controls. OCCmigration and invasion was then assessed counting the
cells at the bottom of the well. Experiments were per-
formed in triplicate.
IL6 inhibition
Inhibition of IL6 receptor was performed by incubation of
OCC and AMS in ultralow attachment plate (Corning)
with specific anti-IL6 receptor antagonist antibody (Abcam,
#ab47215) at the concentration of 1 μg/ml in ultralow at-
tachment 48 well plate (Corning) containing DMEM/F12
(1:1) (Hyclone) basal media supplemented with 2 mM L-
Glutamine (Hyclone), 1 × Non Essential Amino Acid
(NEAA) (Hyclone), PenStrepAmpB (Sigma), 20 ng/ml basic
Fibroblast Growth Factor (bFGF) (Peprotech), 20 ng/ml
Epidermal Growth Factor (EGF) (Peprotech), 5 μg/ml Insu-
lin (Sigma), 2% B27 supplements (Invitrogen) and 4% base-
ment matrigel (BD Biosciences). A control was performed
using an IgG1 isotype antibody. After 24 hours, analysis of
the infiltration was performed by confocal microscopy
(as described above).
Statistical analysis
Student-t tests, Fisher exact tests and chi-square tests
were performed as appropriate. All p-values are two-sided
with statistical significance evaluated at the 0.05 alpha
levels. Ninety-five percent confidence intervals (95% CI)
were calculated to assess the precision of the obtained
estimates.
Results
Cancer cell invasion of amniochorionic membrane
scaffold (AMS) recapitulates peritoneal metastasis
We cultured OCCs in suspension in serum-free media
contining 4% matrigel with small pieces of amniochorio-
nic membrane, referred as amniotic membrane scaffold
(AMS). We obtained OCC aggregates within the 24 first
hours (Figure 1A). Within the 24 first hours OCC aggre-
gates and AMS culture, we could see some of the aggre-
gates in contact with the AMS. We observed adhesion of
eGFP-OVCAR3 and eGFP-SKOV3 aggregates on the
AMS with optic and fluorescent microscope after 24 hours
(Figure 1A). We could take the AMS with a 100μL tip in a
culture dish and wash it with PBS to remove unattached
OCC at the surface of the AMS. The AMS was fixed with
4% paraformaldehyde (PFA) during 10 minutes and ana-
lysed in confocal microscopy.
Forty-eight hours after adhesion, we could demon-
strate infiltration of eGFP-OCC within AMS stromal
cells stained with APC-CD73 using confocal microscopy
(Figure 1B), using Z-stack reconstruction. We could
then study the pattern of OCC infiltration within AMS
and their surrounding amniotic stromal cells. Amniotic
stromal cells CD73+ were located in surface but also
Figure 1 Amniochorionic membrane based 3D model: involvement of the amniochorionic membrane scaffold (AMS) by ovarian cancer
cell lines compared to histologic involvement of the peritoneum. A. Picture by fluorescence microscopy of Ovcar3_eGFP aggregates after
24 hours 3D culture (upper picture). Early attachement (day 1) of the tumoral aggregates on AMS in fluorescence microscopy (lower picture).
B. Early involvement of AMS stained with CD73 APC (red) by Ovcar3_eGFP (green) in confocal microscopy. On this Z-stack reconstruction of a
small tumor, we could see the pattern of eGFP-OCC infiltration within the AMS. Amniotic stromal cells CD73+ were located in surface but also
deeper within AM, surrounding OCCs. C-F. On the histologic sections stained with hematoxylin & eosin, the area below the mesothelium (star) of
a normal peritoneum (C) and amniochorionic membrane (E) was free whereas it was filled with tumoral cells (rhombus) in sections of peritoneal
metastasis (D) and involved AMS at day 2 (F).
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These results were obtained with both cell lines v.
In order to confirm the infiltration we performed histo-
logic examination after hematoxylin & eosin staining and
compared morphologic aspect of AMS infiltration with
peritoneal metastatic nodules (Figure 1C-F). Peritonealnodules were characterized by an infiltration of the
sub-mesothelial region compared to normal peritoneum
(Figure 1C and E). Histologic examination of AMS also
revealed a sub-epithelial region, infiltrated by OCC
72 hours after co-culture, thus recapitulating peritoneal
carcinosis (Figure 1D and F).
Touboul et al. Journal of Translational Medicine 2013, 11:28 Page 5 of 11
http://www.translational-medicine.com/content/11/1/28We established a non-adherent co-culture system of
OCC aggregates and AMS. As we demonstrated AMS
based 3D model could replicate early invasion steps of
EOC infiltration mimicking peritoneal carcinosis, we
went further and used this 3D model to understand the
initial steps involved in invasion.
OCC enrichment in regions with MSC
We have previously demonstrated that the AMS has a
high content in mesenchymal progenitor cells (defined
here by AM CD73+CD90+ cells) [14]. We have also
shown the role of MSCs in resistance to treatment as
well as acquisition of a metastatic phenotype [6]. We
wondered whether MSCs could have a role in the initial
invasion of the AMS. We observed that AMS invasion
was not homogenous indeed most of the tumor implants
were located in regions rich in MSC (70% tumors per
AMS) compared with regions without MSC (30% tumors
per AMS) (NS). For this evaluation, we counted ran-
domly 20 OCC nodules within six different membranes,
three with eGFP-OVCAR3 and three with eGFP-SKOV3
cells. We found that 6 of the 20 nodules were located in
areas rich in MSC markers. The distribution of OCC
nodules was correlated with MSC distribution (Figure 2A
to 2D). Using 3D z-stack reconstruction, we could
measure the tumor depth infiltration of OCC within
AMS and the relations between OCC and surrounding
amniotic stromal cells (Figure 2B, arrows). We found
that tumor infiltration of the AMS was deeper within
regions rich in MSC (26.2 +/− 11.2 μm vs 14.3 +/−
4.3 μm, p<0.05) (Figure E to 2G).
We illustrated that MSCs played a role in a 3D model
of tumor infiltration of OCC. In this model, the presence
of MSC enhanced tumoral aggregates adhesion and infil-
tration. We investigated potential molecular determi-
nants that could play a role in the cross-talk between
OCC and the MSC-niche.
Interaction between MSC and OCC results in increased
migration and invasion through IL6 secretion
To study the role of MSC interaction with OCC in vitro,
we identified MSC population within the AMS used in this
study. As we have previously described, we defined amni-
otic MSCs as CD90+CD73+CD105+CD29+CD45-CD34-
(Figure 3A), [14]. The MSC population represented 15% of
the AMS live cells, as recently reported [14]. They displayed
classical mesenchymal phenotype after cell sorting and ex-
pansion (Figure 3A-B), concordant with previous data [11].
We established a co-culture system with OCCs. Interest-
ingly, as shown in Figure 3C, OCCs and MSCs formed
spontaneously nodular networks where MSC trapped
tumor nodules. We hypothesized that secreted mesencrine
factors could be responsible for increased invasion; we
therefore screened cytokines secreted in a serum-freecytokine-free context in the co-culture setting using cancer
cell culture as a control (Figure 3). IL6, IL8 and Rantes had
increased secretion in co-culture compared to OCC and
MSC monoculture (Figure 3D). Furthermore, TNFa was
demonstrated to orchestrate the ovarian tumor microenvir-
onnement and promote tumor progression [15]. While
many of the cytokines have been described for their role in
cell migration we decided to screen the potential pro-
metastatic mesencrine factor using migration (wound heal-
ing assay and Boyden chamber), and invasion (Matrigel
coated Boyden chamber) assays. In vitro tests revealed that
IL6 was the only molecule increasing both migration and
invasion. Rantes, IL8 and TNFa increased inconstantly cell
migration and invasion (Figure 4). We observed a 1.5 to 15
fold increased migration and >10 fold increased invasion
with IL6.
The effect of the inhibition of IL6 on AMS infiltration
by OCC was tested by the incubation of OCC and AMS in
ultralow attachment plate with a specific anti-IL6 receptor
(IL6R) antagonist antibody (Figure 5). We observed
significant global decreased AMS infiltration when inhibit-
ing IL6R (Figure 5E). The decrease in OCC infiltration
was more important in regions rich in MSC, defined as
CD73+CD90+ cells, indicating that recruitment and 3D in-
vasion of OCC was dependent of IL6 secretion (7.2 fold
versus 2.1 fold, p=0.03) (Figure 5). The control with IgG1
isotype antibody was performed and showed no effect on
OCC infiltration.
Discussion
In this study we illustrated the important role of MSC in
early OCC invasion with a 3D model of metastatic nod-
ule based on an amniochorionic membrane scaffold. We
investigated the interaction between OCC and MSC and
found that IL6 was determinant for OCC to migrate and
infiltrate 3D structures resembling the peritoneum.
Peritoneal mesothelium is the first barrier against spread-
ing ovarian cancer cells. OCC adhere to mesothelial cells
via integrins after MMP2-mediated digestion of vitronectin
and fibronectin [16]. Previous studies showed that the
mesothelium could not be detected under the proliferating
OCC implants suggesting that mesothelial cells are disso-
ciated before peritoneal involvement [17,18]. After breaking
peritoneal mesothelial layer, OCCs can invade the sub-
mesothelial area, constituted by an extra-cellular matrix,
and various cell types including MSCs and fibroblasts.
Tumoral secreted factors such as leucine, leucine-37
(LL-37) or lysophosphatidic acid (LPA) could recruit MSCs
and induce their differentiation in cancer-associated fibro-
blasts (CAF) through signalling pathways involving Rho
kinase, ERK, PLC, and phosphoinositide-3-kinase [19,20].
LPA present in the EOC microenvironment was also
reported to induce STAT3 phosphorylation and ovarian
cancer cell motility through the secretion of IL-6 and IL-8
Figure 2 The distribution of OCC within AMS is following expression of MSC markers. A-D. Confocal microscopy tile scan reconstruction of
Skov3_eGFP (green) distribution after staining with CD90 (red) and CD73 (yellow). The distribution of OCC (B) is following the distribution of
CD90 (C) and CD 73 (D). Using 3D z-stack reconstruction of the tumor, we could measure the tumor depth infiltration of OCC within AMS and
the relations between OCC and surrounding CD73+ amniotic stromal cells (B, arrows). E-F. Confocal tile scan reconstruction showing the
distribution of OCC within AMS in regions rich in MSC (E) and without MSC (F), with their related depth of infiltration. (G). OCC infiltration was
significantly increased in regions rich in MSC (*p<0.05).
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through the AMS after stimulation with recombinant IL6.
Several authors [22-24] showed that MSCs promoted
tumor growth through increased micro-vascularization,
stromal networks, and production of tumor stimulating
paracrine factors. They also demonstrated that these
properties were activated after Mesenchymal Stem Cell
Transition to Tumor-Associated Fibroblasts, through
the paracrine secretion of IL6. We observed increasedproduction of IL6 among other cytokines in co-cultures
of OCCs and MSCs indicating cross-talk between the
two cell lines. Mc Lean et al. demonstrated differences
between MSCs and tumor associated MSCs [25]. They
reported an enhance ovarian cancer stem cell compart-
ment upon the interaction of cancer cells with Tumor
associated mesenchymal cells compare to“wild type”
MSCs [25]. Similarly Liu et al. [26] reported that MSCs
could support breast cancer stem cell compartment
Figure 3 Cytokine array after extraction and culture of the amniotic MSC with OCC. A. By flow cytometry analysis, we identified a
population of MSC defined by negative for CD45 & 34 and positive for CD29, 73, 90 & 105. This population represented 15% of the total cell
population of the amniochorionic membrane. B. Picture of the cultured cells after sorting by optical microscopy. C. Picture of a coculture
between MSC stained with calcein red and OCC (Ovcar3_eGFP in green) by fluorescence microscopy. D. Cytokine array results after MSC and
OCC coculture.
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an increased number of MSCs in most OCCs nodules
within the AMS suggesting an important role in the
early invasion for the constitution of an inflammatory
reactive stroma: “never healing wound theory” [27,28].
As illustrated above the cross-talk between MSCs and
cancer cells and the role of mesencrine factors increas-
ing the metastatic potential have been widely illustrated.
Using a unique 3D model based on an amniotic mem-
brane scaffold we were able to replicate the early
invasion steps, e.g. (i) formation of tumor aggregates,(ii) adhesion to mesothelial layer (iii) microscopic inva-
sion. We illustrated that MSCs could also play a role in
very early attachment and invasion of ovarian cancer
nodules. Indeed the significant enrichment of MSCs
around invasive nodules suggested their ability to pro-
vide the adequate signalling cues for attachment and in-
vasion of ovarian cancer aggregates.
IL6 has been associated with progression in multiple
cancer types, including ovarian cancer. Increased expres-
sion of IL6 and its specific receptor IL6Rα is associated
with disease stage [29]. Recent works also reported the
Figure 4 Wound healing assay and Transwell with Ovcar3 stimulated by IL6, IL8, TNFa and Rantes: A. Wound healing assay: Pictures of
the different conditions at 3, 6 24 and 48 hours. B. Wound healing assay: Representation of the rate of closure for each condition. TNFa, IL6 and
IL8 significantly increased the migration of Ovcar3 compared with Rantes and serum free medium. The positive control used was complete
medium with serum and negative control was serum free medium. C. Transwell: Increased migration was observed with TNFa, IL6 and Rantes
(p<0.001 ***). No migration was observed in the three conditions FBS-, IL8 and TNFa. D. Transwell coated with basement membrane: Increased
invasion was observed with IL6 (p<0.001 ***). No invasion was observed in the four conditions FBS-, IL8, TNFa and Rantes.
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We found that IL6 inhibition limited early adhesion and
infiltration of OCCs in our in-vitro 3D model. Giridhar
et al. showed that IL6 regulated in-vivo adhesion of
OCCs to the omentum through up-regulation of LY75
[30]. Using mice with conditional IL6Ra deficiency, they
found that host IL6 regulation was important for OCC
adhesion [30].
In many cancer IL6 has been described as been up-
regulated [31]. IL6 signaling occurs through a hexameric
complex including specific IL6-alpha receptor (IL6R;glycoprotein gp 80), and a beta-signaling receptor (gp130)
[32]. Dimerization of the receptor induces to the activa-
tion of Janus Tyrosine Kinase signaling and the translo-
cation of a signal transducer and activator of transcription
(STAT) transcription factors [33]. IL6 mainly signals
through STAT3 which translocation to the nucleus induces
a complex transcriptional program resulting in Inflamma-
tion, cell survival, differentiation or prometastatic properties
depending the cellular context [34,35].
There are some limitations in our study. We used AM
instead of peritoneum because it was uneasy to obtain
Figure 5 IL6 receptor (IL6R) inhibition decreased adhesion and infiltration of OCC on AMS. A and C. Confocal tile scan showing
distribution of OCC, i.e. Ovcar3_eGFP (green), within AMS in regions rich in MSC stained with CD90 (red) and CD73 (yellow) (A) and without MSC
(C). B and D. Confocal tile scan showing, after IL6R inhibition, distribution of OCC within AMS in regions rich in MSC (B) and without MSC
(D). E. OCC infiltration was significantly decreased in regions rich in MSC (p<0.001 ***) and in regions without MSC (p<0.05 *).
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necessary for our study. The large resections of periton-
eum mainly occur in patients undergoing debulking sur-
gery for ovarian cancer and therefore could modify
inflammation state of the tissue and bias the experi-
ments. Our model also suffers from the fact that we
couldn’t affirm by which side OCC invaded the AMS.However, our goal was to investigate the relations be-
tween OCC and MSC, and both amniotic and chorionic
membrane is rich in MSC in the same proportion. Fi-
nally, we didn’t define the origin of IL6 secretion. We
showed increased IL6 secretion in co-cultures of OCCs
and MSCs but we did not identify if MSCs, OCCs or
both secreted it. Spaeth et al. co-injected Skov3 with and
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stimulated tumor growth through paracrine production
of IL6 [23]. They found MSCs-induced IL-6 secretion to
be critical for the enhanced proliferation observed in
Skov-3/MSC tumor growth assay [36]. We showed that
IL6 stimulation increased OCC mobility and invasiveness
and inhibiting IL6 receptor decreased OCCs infiltration in
a 3D model. Colomiere et al. reported increased epithelial
to mesenchymal transition (EMT) after EGF treatment of
OCCs [37]. In their model OCCs secretion of IL6 was
increased upon EGF stimulation. Several authors have
demonstrated similar findings in other models [38,39]. In
our model, increased EMT and/or cancer stem cell com-
partment upon IL6 stimulation could explain increased
invasiveness and this remains to be investigated.
Conclusions
In conclusion using an amniotic membrane scaffold might
allow us to follow early invasion in a 3D context. We were
able to demonstrate the essential role of MSCs. Their
interactions with OCCs seemed mediated by IL6, which
has been described determinant for cancer migration and
infiltration mechanisms. Thus cytokine inhibitors inte-
rrupting the cross-talk between OCC and MSC such as
IL6 should be investigated as a therapeutic approach in
ovarian cancer. In-vitro 3D models will therefore be useful
to screen for potential efficient inhibitors of early invasion.
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